Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,759.00-1.92%ETH$2,449.71-0.78%GOLD$4,364.00-0.98%OIL$103.08+0.59%
Smart Investors Daily
CE

NASDAQ · CELC

Celcuity Inc.

Healthcare · Biotechnology

$90.08

Down-$4.59 (-5.10%)

Updated Sep 10, 2026, 11:48 PM

SID Score

4.5/10

Composite research score

Smart Money

54/100

Neutral

Market cap
4.66B
P/E ratio
-27.72
Dividend yield
0.00%
52-week range
$44.42 – $151.02
Volume
708.29K
Avg. volume
1.12M

Price performance

CELC price history

1M range · 0 trading sessions · Daily adjusted prices

CELC does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CELC news

The latest Smart Investors Daily articles mentioning CELC.

Stock researchCompany · Overview

CELC research

Overview

Company profile and research snapshot.

Company profile

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$86.00
Implied upside
—
Analysts
—
CELC recent ratings
DateFirmRatingTarget
Aug 17, 2026CitizensMarket Outperform—
Aug 17, 2026GuggenheimBuy—
Aug 14, 2026NeedhamBuy—
Aug 14, 2026HC Wainwright & Co.Buy—
Aug 14, 2026StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on T

Yahoo · Aug 27, 2026

Celcuity (CELC): Landmark Approval Collides With A Costly Launch

On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company’s history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone […]

Yahoo · Aug 26, 2026

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By